Intellipharmaceutics International Inc. and Aceto Corp.'s common stocks will be delisted from the Nasdaq Stock Market.
Intellipharmaceutics International was suspended from trading March 21, while Aceto was suspended April 3.
Toronto-based Intellipharmaceutics is engaged in the research, development and commercialization of controlled-release and targeted pharmaceutical products, with a particular focus on opioid abuse deterrence.
Meanwhile, Aceto develops and distributes human health products, pharmaceutical ingredients and performance chemicals. The Port Washington, N.Y.-based company filed for Chapter 11 bankruptcy protection in February.
The delisting will be effective 10 days after Nasdaq files a Form 25 to the Securities and Exchange Commission.